Pages that link to "Q77894945"
Jump to navigation
Jump to search
The following pages link to Update on the systolic hypertension in Europe (Syst-Eur) trial. The Syst-Eur Investigators (Q77894945):
Displaying 13 items.
- How well can blood pressure be controlled? Progress report on the Systolic Hypertension in Europe Follow-Up Study (Syst-Eur 2) (Q24799416) (← links)
- Randomised double-blind comparison of placebo and active drugs for effects on risks associated with blood pressure variability in the Systolic Hypertension in Europe trial (Q28654977) (← links)
- Emerging data on calcium-channel blockers: the COHORT study (Q30774952) (← links)
- Methods underpinning national clinical guidelines for hypertension: describing the evidence shortfall (Q33239013) (← links)
- Epidemiology and risk factors for heart failure in the elderly (Q33986255) (← links)
- First line drugs in chronic stable effort angina--the case for newer, longer-acting calcium channel blocking agents (Q34090645) (← links)
- Evolution of calcium antagonists: past, present, and future (Q35079841) (← links)
- Isolated systolic hypertension and the risk of vascular disease. (Q35209077) (← links)
- How will INVEST and other hypertension trials change clinical practice? (Q40675625) (← links)
- Cardiovascular protection and blood pressure reduction: a meta-analysis (Q43782892) (← links)
- Unmet needs in hypertension: challenges and opportunities (Q74299138) (← links)
- The Effects of Eplerenone on the Circadian Blood Pressure Pattern and Left Ventricular Hypertrophy in Patients with Obstructive Sleep Apnea and Resistant Hypertension-A Randomized, Controlled Trial (Q90723530) (← links)
- The impact of acetylsalicylic acid dosed at bedtime on circadian rhythms of blood pressure in the high-risk group of cardiovascular patients-a randomized, controlled trial (Q99595814) (← links)